C3sc51406d 3986..3996

Publisher's Note: Modulation of dorsal root ganglion development by ErbB signaling and the scaffold protein Sorbs3 by Malmquist et al. Development doi:10.1242/dev.084640.

References Malmquist, S. J., Abramsson, A., McGraw, H. F., Linbo, T. H. and Raible, D. W. (2013). Modulation of dorsal root ganglion development by ErbB signaling and the scaffold protein Sorbs3. Development 140, 3986-3996. Bostaille, N., Gauquier, A., Stainier, D. Y. R., Raible, D. W. and Vanhollebeke, B. (2017). Defective adgra2 (gpr124) splicing and function in zebrafish ouchlessmutants. Dev...

A potential role for leukemia inhibitory factor in the increased clonogenicity of human fetal progenitor cells.

1. Liu W, Avent ND, Jones JW, Scott ML, Voak D. Molecular configuration of Rh D epitopes as defined by site-directed mutagenesis and expression of mutant Rh constructs in K562 erythroleukemia cells. Blood. 1999;94:3986-3996. 2. Chang TY, Siegel DL. Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: implications for Rh(D) epitope topology. Blood. 1998;91:3066-30...

Bid to expand horizon of medical students fails.

PAWN: a payload-based mutual authentication scheme for wireless sensor networks

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

PURPOSE This clinical trial investigated the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of CHR-3996, a selective class I histone deacetylase inhibitor. PATIENTS AND METHODS CHR-3996 was administered orally once a day. This phase I trial used a 3+3 dose-escalation design. PK profiles were analyzed by liquid chromatography-tandem mass spectroscopic methods and ...